Oligonucleotide Synthesis Market

Oligonucleotide Synthesis Market by Product (Drug, Synthesized Oligo (Primer), Reagents), Type (Custom, Predesigned), Application (Therapeutic (ASO, siRNA), Research ((PCR, Sequencing, Diagnostics)), End User (Pharma, CROS, CMOs) - Global Forecast to 2027

Report Code: BT 2680 Nov, 2022, by marketsandmarkets.com

[280 Pages Report] The global oligonucleotide synthesis market is projected to reach USD 16.7 billion by 2027 from USD 7.7 billion in 2022, at a CAGR of 16.8% during the forecast period. The major factor driving the growth of this market is the growing focus on personalized genome sequencing that helps determine the best approach for patient care, whether preventive, diagnostic, or therapeutic. Furthermore, increase in government-funded projects is also expected to positively impact the overall growth of the oligonucleotide synthesis market.

Attractive Opportunities in Oligonucleotide Synthesis Market

Oligonucleotide Synthesis Market

To know about the assumptions considered for the study, Request for Free Sample Report

Global Oligonucleotide Synthesis Market Dynamics

Increasing government investments in synthetic biology and genome projects

In recent years, governments in various countries have made significant investments in synthetic biology and genomics projects. These government investments have played a major role in developing new technologies. For instance, the Li Ka Shing Foundation (Hongkong) donated USD 63 million to launch a synthetic biology research institute at the Hong Kong University of Science and Technology (HKUST) in 2019.

Complexities associated with therapeutic oligos

The importance of synthetic oligos as therapeutic drugs for treating diseases has grown significantly in the last decade. Therapeutic oligos are also useful in treating viral infections, respiratory diseases, cancer, and rare diseases such as Duchenne Muscular Dystrophy (DMD), cystic fibrosis, and thrombotic thrombocytopenic purpura. However, there have been various instances wherein many drugs have been withdrawn or failed in clinical trial phases due to complexities such as severe side effects. Such instances could become recurrent and restrain market growth to a certain extent.

Key players in emerging economies

Countries such as China, India, and Singapore and emerging economies such as Brazil provide significant growth opportunities for the oligonucleotide synthesis markets. This potential is mainly due to the increasing R&D investments by various companies in emerging economies of the Asia Pacific and Latin America regions. For instance, in 2020, IDT (US) opened IDT China, an official business entity in China, to better serve its customer base in the region, reach new customers, and provide easier access to its products, including custom DNA and RNA oligos, probes, and primers.

Delivery of oligonucleotide drugs to specific targets

Limitations of the present vector technologies have slowed the progress of gene therapy and antisense therapy for cancer in the clinic. Thus, the development of appropriate delivery systems for targeting therapeutic genes and antisense agents into targeted tumour cells and tissues is one of the potential approaches that have to be further explored in the future to expand gene therapy and antisense therapy against a wide range of cancers.

The oligonucleotide-based drugs segment accounted for the largest share in 2021:

In 2021, the oligonucleotide-based drugs segment held the largest share of the oligonucleotide synthesis market. This is because the oligonucleotide-based drugs, specifically antisense oligonucleotides, and interference RNA, are part of an increasing number of pharmaceutical and biotechnology programs for the treatment of numerous indications, including cancer, cardiovascular, neurodegenerative, neuromuscular, and respiratory diseases.

Oligonucleotide Synthesis Market by Region

To know about the assumptions considered for the study, download the pdf brochure

North America was the largest regional market for oligonucleotide synthesis market in 2021.

North America, comprising the US and Canada, is the largest regional segment in the oligonucleotide synthesis market. The North American market accounted for the largest share of the oligonucleotide synthesis market in 2021. According to the American Cancer Society (ACS), in 2020, the expected total number of new cancer cases diagnosed reached approximately 1,806,590, equivalent to approximately 4,950 new cases each day in the US. Considering the potential of therapeutic oligos in cancer diseases, the oligonucleotide synthesis market is expected to flourish in the coming years

Key Market Players

Key players in the market include Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), LGC Limited (UK), and Maravai Life Sciences (US).

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market size available for years

2020–2027

Base year considered

2021

Forecast period

2022–2027

Forecast units

Value (USD)

Segments covered

Product, Application, End User, and Region

Geographies covered

North America, Europe, Asia Pacific, Latin America, the Middle East & Africa

Companies covered

Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), LGC Limited (UK), Maravai Life Sciences (US), Agilent Technologies, Inc. (US), Eurofins Scientific (Germany), Kaneka Corporation (Japan),  Biolegio B.V (Netherlands), Biolytic Lab Performance Inc. (US),  Microsynth AG (Switzerland), ATDBio Ltd. (UK), Twist Bioscience Corporation (US), Eton Bioscience, Inc. (US), CSBIO (US), Tag Copenhagen A/S (Denmark), Generi Biotech (Czech Republic), Biocomma Limited (China), Hongene Biotech Corporation (China), Hangzhou pharm &chem Co., Ltd (China), Tokyo Chemical Industry Co., Ltd. (Japan), Biogen Inc. (US), Sarepta Therapeutics, Inc. (US), Ionis Pharmaceuticals, Inc. (US), Alnylam Pharmaceuticals, Inc. (US)

This report categorizes the oligonucleotide synthesis market into the following segments and subsegments

By Product
  • Oligonucleotide-based Drugs
  • Synthesized Oligonucleotides
    • By Product
      • Primers
      • Probes
      • DNA Oligos
      • RNA Oligos
      • Other Synthesized Oligos
    • By Type
      • Customized Oligos
      • Predesigned Oligos
  • Reagents
  • Equipment  
By Application
  • Research Applications
  • Diagnostic Applications
  • Therapeutic Applications
    • By Type
      • Antisense Oligonucleotide-based Therapies 
      • siRNA Oligonucleotide-based Therapies
      • CpG Oligonucleotide-based Therapies
    •  By Disease Type
      • Neurological Disorders
      • Infectious Diseases
      • Other Diseases
By End User
  • Hospitals
  • Pharmaceutical & Biotechnology Companies
  • Diagnostic Laboratories
  • CROs and CMOs
  • Academic Research Institutes
By Region
  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • RoE
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa

Recent Developments

  • In 2020, Danaher Corporation (US) opened IDT China, an official business entity, to better serve its regional customer base, reach out to new customers, and provide easier access to its complete portfolio of industry-leading products.
  • In 2020, Danaher (US) acquired the Biopharma business from General Electric Company’s (US) Life Sciences division. It was renamed Cytiva and will act as a standalone operating company within Danaher’s Life Sciences segment. This acquisition strengthened Danaher’s position in the oligo synthesizer and reagents market.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

 

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 49)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE 
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED
    1.4 CURRENCY CONSIDERED 
    1.5 LIMITATIONS 
    1.6 STAKEHOLDERS 
    1.7 SUMMARY OF CHANGES 
 
2 RESEARCH METHODOLOGY (Page No. - 54)
    2.1 RESEARCH DATA 
          FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                    FIGURE 2 BREAKDOWN OF PRIMARIES
    2.2 MARKET ESTIMATION METHODOLOGY 
          FIGURE 3 MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (RESEARCH AND DIAGNOSTIC MARKET)
          FIGURE 4 MARKET SIZE ESTIMATION- COMPANY REVENUE ANALYSIS-BASED ESTIMATION (THERAPEUTIC MARKET)
          FIGURE 5 OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE (USD MILLION)
          FIGURE 6 OLIGONUCLEOTIDE SYNTHESIS MARKET: FINAL CAGR PROJECTIONS (2022−2027)
          FIGURE 7 OLIGONUCLEOTIDE SYNTHES MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
          FIGURE 8 OLIGONUCLEOTIDE SYNTHESIS: SEGMENTAL ASSESSMENT
           2.2.1 INSIGHTS FROM PRIMARY EXPERTS
                    FIGURE 9 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
    2.3 DATA TRIANGULATION 
          FIGURE 10 DATA TRIANGULATION METHODOLOGY
    2.4 STUDY ASSUMPTIONS 
    2.5 RISK ANALYSIS 
 
3 EXECUTIVE SUMMARY (Page No. - 63)
    FIGURE 11 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
    FIGURE 12 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
    FIGURE 13 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    FIGURE 14 GEOGRAPHICAL SNAPSHOT OF OLIGONUCLEOTIDE SYNTHESIS MARKET
 
4 PREMIUM INSIGHTS (Page No. - 66)
    4.1 OLIGONUCLEOTIDE SYNTHESIS MARKET OVERVIEW 
          FIGURE 15 INCREASING USE OF SYNTHETIC OLIGOS TO DRIVE MARKET
    4.2 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE, BY APPLICATION AND COUNTRY (2021) 
          FIGURE 16 THERAPEUTIC APPLICATION SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2021
    4.3 OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE, BY PRODUCT, 2022 VS. 2027 
          FIGURE 17 OLIGONUCLEOTIDE-BASED DRUGS SEGMENT TO DOMINATE MARKET IN 2027
    4.4 OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE, BY APPLICATION, 2022 
          FIGURE 18 THERAPEUTIC APPLICATION SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2022
    4.5 OLIGONUCLEOTIDE SYNTHESIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 19 ASIA PACIFIC COUNTRIES TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 69)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
           FIGURE 20 OLIGONUCLEOTIDE SYNTHESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Increasing use of synthesized oligos in therapeutic applications
                                TABLE 1 FDA-APPROVED OLIGONUCLEOTIDE-BASED THERAPIES
                                FIGURE 21 ONGOING CLINICAL TRIALS BY TOP 10 THERAPEUTIC AREAS
                    5.2.1.2 Increasing government investments in synthetic biology and genome projects
                    5.2.1.3 Growing focus on personalized medicine
           5.2.2 RESTRAINTS
                    5.2.2.1 Complexities associated with therapeutic oligos
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Increasing R&D investments by key players in emerging economies
           5.2.4 CHALLENGES
                    5.2.4.1 Delivery of oligonucleotide drugs to specific targets
    5.3 RANGES/SCENARIOS 
          FIGURE 22 SPECTRUM OF SCENARIOS BASED ON IMPACT OF UNCERTAINTIES ON GROWTH OF OLIGONUCLEOTIDE SYNTHESIS MARKET
    5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
          FIGURE 23 REVENUE SHIFT AND NEW REVENUE POCKETS
    5.5 SUPPLY CHAIN ANALYSIS 
          FIGURE 24 DIRECT DISTRIBUTION STRATEGY PREFERRED BY PROMINENT COMPANIES
           5.5.1 KEY INFLUENCERS
    5.6 VALUE CHAIN ANALYSIS 
          FIGURE 25 VALUE CHAIN ANALYSIS—MAXIMUM VALUE ADDED DURING MANUFACTURING PHASE
    5.7 ECOSYSTEM ANALYSIS 
          FIGURE 26 ECOSYSTEM ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET
           5.7.1 ROLE IN ECOSYSTEM
    5.8 TECHNOLOGICAL ANALYSIS 
           5.8.1 SOLID-PHASE SYNTHESIS
           5.8.2 LIQUID-PHASE SYNTHESIS
    5.9 INDICATIVE PRICING MODEL ANALYSIS 
          TABLE 2 PRICING ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS
    5.10 TRADE DATA 
           TABLE 3 IMPORT DATA FOR OLIGONUCLEOTIDES, BY COUNTRY, 2016–2020 (USD THOUSAND)
    5.11 REGULATORY ANALYSIS 
           5.11.1 GOVERNMENT REGULATIONS FOR OLIGONUCLEOTIDE-BASED DRUGS
           5.11.2 GOVERNMENT REGULATIONS FOR OLIGONUCLEOTIDE-BASED DRUGS: GOOD MANUFACTURING PRACTICES (GMP)
           5.11.3 ISO 13485
           5.11.4 IVD & ASR
    5.12 PATENT ANALYSIS 
           FIGURE 27 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR OLIGONUCLEOTIDE SYNTHESIS PATENTS (JANUARY 2012–OCTOBER 2022)
           TABLE 4 INDICATIVE LIST OF PATENTS IN OLIGONUCLEOTIDE SYNTHESIS MARKET
    5.13 PORTER’S FIVE FORCES ANALYSIS 
           TABLE 5 PORTER’S FIVE FORCES ANALYSIS
           5.13.1 DEGREE OF COMPETITION
           5.13.2 BARGAINING POWER OF SUPPLIERS
           5.13.3 BARGAINING POWER OF BUYERS
           5.13.4 THREAT OF SUBSTITUTES
           5.13.5 THREAT OF NEW ENTRANTS
    5.14 KEY CONFERENCES AND EVENTS IN 2022–2023 
           TABLE 6 OLIGONUCLEOTIDE SYNTHESIS MARKET: LIST OF CONFERENCES AND EVENTS
    5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 
           FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS
    5.16 KEY BUYING CRITERIA BY END USERS 
           FIGURE 29 BUYING CRITERIA OF END USERS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS
 
6 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT (Page No. - 91)
    6.1 INTRODUCTION 
          TABLE 7 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
          TABLE 8 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PRODUCT, BY REGION, 2020–2027 (USD MILLION)
          TABLE 9 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PRODUCT, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 10 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PRODUCT, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 11 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PRODUCT, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 12 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PRODUCT, BY COUNTRY, 2020–2027 (USD MILLION)
    6.2 OLIGONUCLEOTIDE-BASED DRUGS 
           6.2.1 OLIGONUCLEOTIDE-BASED DRUGS DOMINATED MARKET IN 2021
                    TABLE 13 OLIGONUCLEOTIDE-BASED THERAPIES
                    TABLE 14 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OLIGONUCLEOTIDE-BASED DRUGS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 15 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OLIGONUCLEOTIDE-BASED DRUGS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 16 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OLIGONUCLEOTIDE-BASED DRUGS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 17 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OLIGONUCLEOTIDE-BASED DRUGS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 18 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OLIGONUCLEOTIDE-BASED DRUGS, BY COUNTRY, 2020–2027 (USD MILLION)
    6.3 SYNTHESIZED OLIGONUCLEOTIDES 
          TABLE 19 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020–2027 (USD MILLION)
          TABLE 20 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 21 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 22 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 23 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
           6.3.1 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT
                    TABLE 24 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION)
                    6.3.1.1 Primers
                               6.3.1.1.1 Increasing applications for oligo primers in DNA sequencing and molecular diagnostics to drive segment
                                              TABLE 25 PRIMERS: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020–2027 (USD MILLION)
                                              TABLE 26 PRIMERS: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 27 PRIMERS: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 28 PRIMERS: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 29 PRIMERS: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
                    6.3.1.2 Probes
                               6.3.1.2.1 Probes to detect various infectious agents and altered DNA/RNA sequences
                                              TABLE 30 PROBES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020–2027 (USD MILLION)
                                              TABLE 31 PROBES: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 32 PROBES: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 33 PROBES: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 34 PROBES: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
                    6.3.1.3 DNA oligos
                               6.3.1.3.1 Innovations in DNA oligos to eliminate time-consuming PCR and drive segment
                                              TABLE 35 DNA OLIGOS: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020–2027 (USD MILLION)
                                              TABLE 36 DNA OLIGOS: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 37 DNA OLIGOS: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 38 DNA OLIGOS: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 39 DNA OLIGOS: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
                    6.3.1.4 RNA oligos
                               6.3.1.4.1 RNA oligos to be used as molecular diagnostic tools
                                              TABLE 40 RNA OLIGOS: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020–2027 (USD MILLION)
                                              TABLE 41 RNA OLIGOS: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 42 RNA OLIGOS: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 43 RNA OLIGOS: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 44 RNA OLIGOS: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
                    6.3.1.5 Other synthesized oligonucleotides
                                TABLE 45 OTHER SYNTHESIZED OLIGONUCLEOTIDES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 46 OTHER SYNTHESIZED OLIGONUCLEOTIDES: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 47 OTHER SYNTHESIZED OLIGONUCLEOTIDES: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 48 OTHER SYNTHESIZED OLIGONUCLEOTIDES: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 49 OTHER SYNTHESIZED OLIGONUCLEOTIDES: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
           6.3.2 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE
                    TABLE 50 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION)
                    6.3.2.1 Custom oligonucleotides
                               6.3.2.1.1 Surge in demand in clinical and preclinical studies to propel segment
                                              TABLE 51 CUSTOM OLIGONUCLEOTIDES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020–2027 (USD MILLION)
                                              TABLE 52 CUSTOM OLIGONUCLEOTIDES: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 53 CUSTOM OLIGONUCLEOTIDES: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 54 CUSTOM OLIGONUCLEOTIDES: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 55 CUSTOM OLIGONUCLEOTIDES: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
                    6.3.2.2 Predesigned oligos
                               6.3.2.2.1 Predesigned oligos to be used in routine research applications, such as PCR and sequencing
                                              TABLE 56 PREDESIGNED OLIGOS: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020–2027 (USD MILLION)
                                              TABLE 57 PREDESIGNED OLIGOS: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 58 PREDESIGNED OLIGOS: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 59 PREDESIGNED OLIGOS: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 60 PREDESIGNED OLIGOS: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
    6.4 REAGENTS 
           6.4.1 GROWING APPLICATIONS OF OLIGOS IN SEQUENCING, DRUG DESIGN, AND GENE SYNTHESIS TO PROPEL MARKET
                    TABLE 61 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR REAGENTS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 62 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 63 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 64 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 65 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION)
    6.5 EQUIPMENT 
           6.5.1 TECHNOLOGICAL INNOVATIONS IN OLIGONUCLEOTIDE SYNTHESIZERS TO STIMULATE MARKET
                    TABLE 66 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR EQUIPMENT, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 67 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 68 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 69 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 70 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
 
7 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION (Page No. - 122)
    7.1 INTRODUCTION 
          TABLE 71 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
          TABLE 72 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
          TABLE 73 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR APPLICATION, BY REGION, 2020–2027 (USD MILLION)
          TABLE 74 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR APPLICATION, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 75 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR APPLICATION, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 76 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR APPLICATION, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 77 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR APPLICATION, BY COUNTRY, 2020–2027 (USD MILLION)
    7.2 THERAPEUTIC APPLICATIONS 
          TABLE 78 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
          TABLE 79 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATION, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 80 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 81 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 82 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
           7.2.1 THERAPEUTIC APPLICATIONS MARKET, BY TYPE
                    TABLE 83 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                    7.2.1.1 Antisense oligonucleotide-based therapies
                               7.2.1.1.1 Antisense oligos to form basis of therapies in clinical trials
TABLE 84 ANTISENSE OLIGONUCLEOTIDE-BASED THERAPIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 85 ANTISENSE OLIGONUCLEOTIDE-BASED THERAPIES: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 86 ANTISENSE OLIGONUCLEOTIDE-BASED THERAPIES: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 87 ANTISENSE OLIGONUCLEOTIDE-BASED THERAPIES: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 88 ANTISENSE OLIGONUCLEOTIDE-BASED THERAPIES: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    7.2.1.2 siRNA oligonucleotide-based therapies
                               7.2.1.2.1 Ease of drug target identification with bioinformatics to boost segment
TABLE 89 SIRNA OLIGONUCLEOTIDE-BASED THERAPIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 90 SIRNA OLIGONUCLEOTIDE-BASED THERAPIES: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 91 SIRNA OLIGONUCLEOTIDE-BASED THERAPIES: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 92 SIRNA OLIGONUCLEOTIDE-BASED THERAPIES: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 93 SIRNA OLIGONUCLEOTIDE-BASED THERAPIES: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    7.2.1.3 CpG oligonucleotide-based therapies
                               7.2.1.3.1 CpG ODNs to show significant potential for variety of disease treatments, including cancer
TABLE 94 CPG OLIGONUCLEOTIDE-BASED THERAPIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 95 CPG OLIGONUCLEOTIDE-BASED THERAPIES: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 96 CPG OLIGONUCLEOTIDE-BASED THERAPIES: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 97 CPG OLIGONUCLEOTIDE-BASED THERAPIES: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 98 CPG OLIGONUCLEOTIDE-BASED THERAPIES: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
           7.2.2 THERAPEUTIC APPLICATIONS MARKET, BY DISEASE TYPE
                    TABLE 99 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                    7.2.2.1 Neurological disorders
                               7.2.2.1.1 Neurological disorders dominated market by disease type in 2020
                                              TABLE 100 NEUROLOGICAL DISORDERS: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
                                              TABLE 101 NEUROLOGICAL DISORDERS: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 102 NEUROLOGICAL DISORDERS: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 103 NEUROLOGICAL DISORDERS: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 104 NEUROLOGICAL DISORDERS: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    7.2.2.2 Infectious diseases
                               7.2.2.2.1 Antisense therapies and oligonucleotide aptamers to be significant in treatment and diagnosis of infectious diseases
                                              TABLE 105 INFECTIOUS DISEASES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
                                              TABLE 106 INFECTIOUS DISEASES: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 107 INFECTIOUS DISEASES: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 108 INFECTIOUS DISEASES: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 109 INFECTIOUS DISEASES: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    7.2.2.3 Other diseases
                                TABLE 110 OTHER DISEASES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 111 OTHER DISEASES: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 112 OTHER DISEASES: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 113 OTHER DISEASES: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 114 OTHER DISEASES: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
    7.3 RESEARCH APPLICATIONS 
          TABLE 115 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 116 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
          TABLE 117 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 118 EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 119 ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 120 LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
           7.3.1 PCR
                    7.3.1.1 Increasing use of PCR in research to drive market
                                TABLE 121 PCR: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 122 PCR: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 123 PCR: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 124 PCR: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 125 PCR: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
           7.3.2 SEQUENCING
                    7.3.2.1 Advancements in technologies and low cost of DNA sequencing to boost segment
                                TABLE 126 SEQUENCING: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 127 SEQUENCING: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 128 SEQUENCING: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 129 SEQUENCING: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 130 SEQUENCING: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
           7.3.3 OTHER RESEARCH APPLICATIONS
                    TABLE 131 OTHER RESEARCH APPLICATIONS: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 132 OTHER RESEARCH APPLICATIONS: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 133 OTHER RESEARCH APPLICATIONS: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 134 OTHER RESEARCH APPLICATIONS: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 135 OTHER RESEARCH APPLICATIONS: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
    7.4 DIAGNOSTIC APPLICATIONS 
           7.4.1 GROWING FIELDS OF MOLECULAR DIAGNOSTICS (MDX) AND IN VITRO DIAGNOSTICS (IVD) TO AUGMENT SEGMENT
                    TABLE 136 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 137 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 138 EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 139 ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 140 LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
 
8 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER (Page No. - 157)
    8.1 INTRODUCTION 
          TABLE 141 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
          TABLE 142 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR END USER, BY REGION, 2020–2027 (USD MILLION)
          TABLE 143 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR END USER, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 144 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR END USER, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 145 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR END USER, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 146 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR END USER, BY COUNTRY, 2020–2027 (USD MILLION)
    8.2 HOSPITALS 
           8.2.1 INCREASING FDA-APPROVALS FOR OLIGONUCLEOTIDE-BASED DRUGS TO STIMULATE MARKET
                    TABLE 147 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 148 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 149 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 150 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 151 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2020–2027 (USD MILLION)
    8.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 
           8.3.1 GROWING APPLICATIONS OF OLIGOS IN DRUG DISCOVERY AND THERAPEUTICS TO DRIVE SEGMENT
                    TABLE 152 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 153 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 154 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 155 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 156 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
    8.4 DIAGNOSTIC LABORATORIES 
           8.4.1 INCREASING SIGNIFICANCE OF OLIGOS IN MOLECULAR DIAGNOSTICS TO STIMULATE GROWTH
                    TABLE 157 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 158 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 159 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 160 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 161 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)
    8.5 CONTRACT RESEARCH ORGANIZATIONS & CONTRACT MANUFACTURING ORGANIZATIONS 
           8.5.1 WIDE RANGE OF CUSTOMIZED OLIGO SERVICES TO AID GROWTH
                    TABLE 162 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 163 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 164 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 165 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 166 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2020–2027 (USD MILLION)
    8.6 ACADEMIC RESEARCH & INSTITUTES 
           8.6.1 ACADEMIC AND GOVERNMENT RESEARCHERS TO USE OLIGOS FOR GENOMIC TECHNOLOGIES
                    TABLE 167 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 168 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 169 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 170 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 171 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
 
9 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION (Page No. - 172)
    9.1 INTRODUCTION 
          TABLE 172 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION, 2020–2027 (USD MILLION)
    9.2 NORTH AMERICA 
          FIGURE 30 NORTH AMERICA: MARKET SNAPSHOT
          TABLE 173 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 174 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
          TABLE 175 NORTH AMERICA: SYNTHESIZES OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
          TABLE 176 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDE SYNTHESIS MARKET, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 177 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
          TABLE 178 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 179 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
          TABLE 180 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 181 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.2.1 US
                    9.2.1.1 Government initiatives and strategic developments to drive market
                                TABLE 182 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 183 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 184 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 185 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                TABLE 186 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 187 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                                TABLE 188 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 189 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.2.2 CANADA
                    9.2.2.1 Strong research infrastructure and availability of funding to support market
                                TABLE 190 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 191 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 192 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 193 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                TABLE 194 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 195 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                                TABLE 196 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 197 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
    9.3 EUROPE 
          TABLE 198 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 199 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
          TABLE 200 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION)
          TABLE 201 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 202 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
          TABLE 203 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 204 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
          TABLE 205 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 206 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.1 UK
                    9.3.1.1 Increasing strategic developments by market players to propel market
                                TABLE 207 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 208 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 209 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 210 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                TABLE 211 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 212 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                                TABLE 213 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 214 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.2 GERMANY
                    9.3.2.1 Presence of several academic & research institutes to aid growth
                                TABLE 215 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 216 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 217 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 218 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                TABLE 219 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 220 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                                TABLE 221 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 222 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.3 FRANCE
                    9.3.3.1 Government initiatives to strengthen R&D activities and drive market
                                TABLE 223 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 224 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 225 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 226 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                TABLE 227 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 228 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                                TABLE 229 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 230 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.4 ITALY
                    9.3.4.1 Increasing research activities in life sciences to boost market
                                TABLE 231 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 232 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 233 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 234 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                TABLE 235 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 236 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                                TABLE 237 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 238 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.5 SPAIN
                    9.3.5.1 Government initiatives for development of biomedicine and healthcare sectors to stimulate market
                                TABLE 239 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 240 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 241 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 242 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                TABLE 243 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 244 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                                TABLE 245 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 246 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.6 REST OF EUROPE
                    TABLE 247 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                    TABLE 248 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION)
                    TABLE 249 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 250 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                    TABLE 251 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 252 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                    TABLE 253 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 254 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
    9.4 ASIA PACIFIC 
          FIGURE 31 ASIA PACIFIC: MARKET SNAPSHOT
          TABLE 255 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 256 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
          TABLE 257 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION)
          TABLE 258 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 259 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
          TABLE 260 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 261 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
          TABLE 262 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 263 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.4.1 CHINA
                    9.4.1.1 Increasing focus of Chinese biopharma companies to aid market
                                TABLE 264 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 265 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 266 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 267 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                TABLE 268 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 269 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                                TABLE 270 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 271 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.4.2 JAPAN
                    9.4.2.1 Increasing awareness of oligos through conferences and workshops to drive market
                                TABLE 272 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 273 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 274 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 275 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                TABLE 276 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 277 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                                TABLE 278 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 279 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.4.3 INDIA
                    9.4.3.1 Strong initiatives to develop bio clusters and increased adoption of genomic technologies to aid market
                                TABLE 280 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 281 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 282 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 283 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                TABLE 284 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 285 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                                TABLE 286 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 287 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.4.4 REST OF ASIA PACIFIC
                    TABLE 288 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                    TABLE 289 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION)
                    TABLE 290 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 291 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                    TABLE 292 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 293 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                    TABLE 294 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 295 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
    9.5 LATIN AMERICA 
          TABLE 296 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 297 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
          TABLE 298 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION)
          TABLE 299 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 300 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
          TABLE 301 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 302 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
          TABLE 303 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 304 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.5.1 BRAZIL
                    9.5.1.1 Growing prevalence of infectious and non-infectious diseases to support market
                                TABLE 305 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 306 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 307 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 308 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                TABLE 309 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 310 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                                TABLE 311 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 312 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.5.2 MEXICO
                    9.5.2.1 Increasing research in synthetic biology to drive market
                                TABLE 313 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 314 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 315 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 316 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                TABLE 317 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 318 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                                TABLE 319 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 320 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.5.3 REST OF LATIN AMERICA
                    TABLE 321 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                    TABLE 322 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION)
                    TABLE 323 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 324 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                    TABLE 325 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 326 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                    TABLE 327 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 328 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
    9.6 MIDDLE EAST & AFRICA 
           9.6.1 GROWING ACCEPTANCE OF PERSONALIZED MEDICINE TO PROPEL MARKET
                    TABLE 329 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                    TABLE 330 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION)
                    TABLE 331 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 332 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                    TABLE 333 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 334 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                    TABLE 335 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 336 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
 
10 COMPETITIVE LANDSCAPE (Page No. - 244)
     10.1 INTRODUCTION 
     10.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS 
             TABLE 337 OLIGONUCLEOTIDE SYNTHESIS MARKET: KEY STRATEGIES ADOPTED
     10.3 MARKET SHARE ANALYSIS 
             FIGURE 32 OLIGONUCLEOTIDE SYNTHESIS MARKET: MARKET SHARE ANALYSIS (RESEARCH AND DIAGNOSTIC MARKET), 2021
             TABLE 338 OLIGONUCLEOTIDE SYNTHESIS MARKET (FOR RESEARCH AND DIAGNOSTIC MARKET): DEGREE OF COMPETITION
             FIGURE 33 OLIGONUCLEOTIDE SYNTHESIS MARKET: MARKET SHARE ANALYSIS (THERAPEUTIC MARKET), 2021
             TABLE 339 OLIGONUCLEOTIDE SYNTHESIS MARKET (FOR THERAPEUTICS MARKET): DEGREE OF COMPETITION
     10.4 REVENUE ANALYSIS: OLIGONUCLEOTIDE SYNTHESIS MARKET 
             FIGURE 34 REVENUE ANALYSIS FOR KEY COMPANIES (2019–2021)
     10.5 COMPANY EVALUATION MATRIX 
             FIGURE 35 OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX, 2021
             10.5.1 STARS
             10.5.2 EMERGING LEADERS
             10.5.3 PERVASIVE PLAYERS
             10.5.4 PARTICIPANTS
     10.6 COMPANY EVALUATION MATRIX: START-UPS/SMES 
             FIGURE 36 OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2021
             10.6.1 PROGRESSIVE COMPANIES
             10.6.2 STARTING BLOCKS
             10.6.3 RESPONSIVE COMPANIES
             10.6.4 DYNAMIC COMPANIES
     10.7 COMPETITIVE BENCHMARKING OF START-UPS/SMES 
             TABLE 340 OLIGONUCLEOTIDE SYNTHESIS MARKET: DETAILED LIST OF KEY START-UPS/SMES
             TABLE 341 OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPETITIVE BENCHMARKING OF KEY START-UPS/SMES
     10.8 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS 
             10.8.1 COMPANY FOOTPRINT
                        TABLE 342 COMPANY FOOTPRINT ANALYSIS: KEY PLAYERS
             10.8.2 PRODUCT FOOTPRINT
                        TABLE 343 PRODUCT FOOTPRINT ANALYSIS: KEY PLAYERS
             10.8.3 APPLICATION FOOTPRINT
                        TABLE 344 APPLICATION FOOTPRINT ANALYSIS: KEY PLAYERS
             10.8.4 REGIONAL FOOTPRINT
                        TABLE 345 REGIONAL FOOTPRINT ANALYSIS: KEY PLAYERS
     10.9 COMPETITIVE SCENARIO AND TRENDS 
             10.9.1 PRODUCT LAUNCHES
                        TABLE 346 OLIGONUCLEOTIDE SYNTHESIS MARKET: PRODUCT LAUNCHES (JANUARY 2019–OCTOBER 2022)
             10.9.2 DEALS
                        TABLE 347 OLIGONUCLEOTIDE SYNTHESIS MARKET: DEALS (JANUARY 2019–OCTOBER 2022)
             10.9.3 OTHER DEVELOPMENTS
                        TABLE 348 OLIGONUCLEOTIDE SYNTHESIS MARKET: OTHER DEVELOPMENTS (JANUARY 2019–OCTOBER 2022)
 
11 COMPANY PROFILES (Page No. - 260)
     11.1 KEY PLAYERS 
(Business Overview, Products/Services/Solutions Offered, Recent Developments, and MnM View)*
             11.1.1 DANAHER CORPORATION
                        TABLE 349 DANAHER CORPORATION: COMPANY OVERVIEW
                        FIGURE 37 DANAHER CORPORATION: COMPANY SNAPSHOT
             11.1.2 THERMO FISHER SCIENTIFIC INC.
                        TABLE 350 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
                        FIGURE 38 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
             11.1.3 MERCK KGAA
                        TABLE 351 MERCK KGAA: COMPANY OVERVIEW
                        FIGURE 39 MERCK KGAA: COMPANY SNAPSHOT
             11.1.4 EUROFINS SCIENTIFIC
                        TABLE 352 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
                        FIGURE 40 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT
             11.1.5 LGC LIMITED
                        TABLE 353 LGC LIMITED: COMPANY OVERVIEW
                        FIGURE 41 LGC LIMITED: COMPANY SNAPSHOT
             11.1.6 AGILENT TECHNOLOGIES, INC.
                        TABLE 354 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
                        FIGURE 42 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
             11.1.7 KANEKA CORPORATION
                        TABLE 355 KANEKA CORPORATION: COMPANY OVERVIEW
                        FIGURE 43 KANEKA CORPORATION: COMPANY SNAPSHOT
             11.1.8 MARAVAI LIFESCIENCES
                        TABLE 356 MARAVAI LIFESCIENCES: COMPANY OVERVIEW
                        FIGURE 44 MARAVAI LIFESCIENCES: COMPANY SNAPSHOT
             11.1.9 BIOLEGIO B.V.
                        TABLE 357 BIOLEGIO B.V.: COMPANY OVERVIEW
             11.1.10 BIOLYTIC LAB PERFORMANCE INC.
                        TABLE 358 BIOLYTIC LAB PERFORMANCE INC.: COMPANY OVERVIEW
             11.1.11 MICROSYNTH AG
                        TABLE 359 MICROSYNTH AG: COMPANY OVERVIEW
     11.2 THERAPEUTIC PLAYERS 
             11.2.1 BIOGEN INC.
                        TABLE 360 BIOGEN INC.: COMPANY OVERVIEW
                        FIGURE 45 BIOGEN INC.: COMPANY SNAPSHOT
             11.2.2 SAREPTA THERAPEUTICS, INC.
                        TABLE 361 SAREPTA THERAPEUTICS INC.: COMPANY OVERVIEW
                        FIGURE 46 SAREPTA THERAPEUTICS INC.: COMPANY SNAPSHOT
             11.2.3 IONIS PHARMACEUTICALS, INC.
                        TABLE 362 IONIS PHARMACEUTICALS, INC.: COMPANY OVERVIEW
                        FIGURE 47 IONIS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
             11.2.4 ALNYLAM PHARMACEUTICALS, INC.
                        TABLE 363 ALNYLAM PHARMACEUTICALS, INC.: COMPANY OVERVIEW
                        FIGURE 48 ALNYLAM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
* Business Overview, Products/Services/Solutions Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
     11.3 OTHER PLAYERS 
             11.3.1 ADTBIO LTD.
             11.3.2 TWIST BIOSCIENCE CORPORATION
             11.3.3 ETON BIOSCIENCE, INC.
             11.3.4 CSBIO
             11.3.5 TAG COPENHAGEN A/S
             11.3.6 GENERI BIOTECH
             11.3.7 BIOCOMMA LIMITED
             11.3.8 HONGENE BIOTECH CORPORATION
             11.3.9 HANGZHOU PHARM &CHEM CO., LTD.
             11.3.10 TOKYO CHEMICAL INDUSTRY CO., LTD. (TCI)
 
12 APPENDIX (Page No. - 307)
     12.1 DISCUSSION GUIDE 
     12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     12.3 CUSTOMIZATION OPTIONS 
     12.4 RELATED REPORTS 
     12.5 AUTHOR DETAILS 

This study involved four major activities in estimating the current size of the oligonucleotide synthesis market. Exhaustive secondary research was conducted to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study. The secondary sources used for this study include annual reports, SEC filings, investor presentations, World Health Organization (WHO), Food and Drug Administration (FDA), National Center for Biotechnology Information (NCBI), Industry Association of Synthetic Biology (IASB), Biotechnology Innovation Organization (BIO), and Genome Canada. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information and assess the prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Oligonucleotide Synthesis Market Size, and Share

*Others include sales managers, marketing managers, and product managers.

Note: Tiers are defined based on a company’s total revenue. As of 2021, Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the oligonucleotide synthesis market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive secondary research.
  • The revenues generated from the oligonucleotide synthesis business of leading players have been determined through primary and secondary research.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Data Triangulation

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. Data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, and forecast the global oligonucleotide synthesis market based on the product, application, end user, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, and opportunities)
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall oligonucleotide synthesis market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa
  • To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the oligonucleotide synthesis market.

Available Customizations

With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:

Company Information

  • An additional five company profiles
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
BT 2680
Published ON
Nov, 2022
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Oligonucleotide Synthesis Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback